Antiprotozoal Drugs

Antiprotozoal drugs are active pharmaceutical ingredients designed to treat infections caused by protozoan parasites such as Giardia, Trypanosoma, Toxoplasma, Leishmania, and Plasmodium species. These APIs act through diverse mechanisms, including inhibition of nucleic acid synthesis, disruption of mitochondrial function, interference with folate pathways, or generation of reactive intermediates that damage parasitic DNA and proteins. Antiprotozoal agents encompass nitroimidazoles, antimalarial compounds, antimonial drugs, diamidines, and novel targeted molecules developed to address increasing drug resistance. They are used for acute and chronic infections affecting the gastrointestinal tract, bloodstream, central nervous system, and visceral organs. Pharmaceutical formulations include tablets, suspensions, injectables, and fixed-dose combinations tailored for global health needs. Antiprotozoal drugs play a vital role in reducing morbidity, preventing severe complications, and supporting control programs for major tropical diseases. Ongoing research continues to expand therapeutic options, improve safety profiles, and overcome resistance in protozoan pathogens.